HONG KONG — In November 2014, a little less than six years ago, Chinese scientist Jingwu Zang set up his own drug company, Third Venture Biopharma. The former head of China R&D for GlaxoSmithKline wanted to develop innovative biologics that can treat various cancers and autoimmune diseases.
A domestic merger, a slew of in-licensing deals, and a Nasdaq listing later, the Shanghai-based biotech — now called I-Mab Biopharma — is hanging on to one of its self-discovered drug assets, a highly coveted anti-CD47 monoclonal antibody, as its ticket into a global race for the next class of promising cancer immunotherapies.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
